Abeona Therapeutics Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: ABEO · Form: DEF 14A · Filed: Mar 19, 2024 · CIK: 318306
| Field | Detail |
|---|---|
| Company | Abeona Therapeutics Inc. (ABEO) |
| Form Type | DEF 14A |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Abeona Therapeutics, DEF 14A, Annual Meeting, Proxy Statement, Virtual Meeting
TL;DR
<b>Abeona Therapeutics Inc. will hold its virtual Annual Meeting of Stockholders on April 24, 2024, urging prompt return of proxy cards.</b>
AI Summary
ABEONA THERAPEUTICS INC. (ABEO) filed a Proxy Statement (DEF 14A) with the SEC on March 19, 2024. The Annual Meeting of Stockholders for Abeona Therapeutics Inc. will be held virtually on April 24, 2024, at 9:00 a.m. Eastern Time. Stockholders can attend, vote, and submit questions via a live webcast at www.virtualshareholdermeeting.com/ABEO2024. The proxy statement provides details on the business to be considered at the meeting. Stockholders are urged to mark, sign, date, and return their proxy cards promptly. Proxies can be revoked by attending the meeting virtually and requesting to vote, submitting a later-dated proxy, or providing written notice to the secretary.
Why It Matters
For investors and stakeholders tracking ABEONA THERAPEUTICS INC., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and procedures for the upcoming annual meeting, crucial for shareholder participation and voting. The virtual format and webcast link are provided, ensuring accessibility for stockholders to engage with company management and vote on important matters.
Risk Assessment
Risk Level: low — ABEONA THERAPEUTICS INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
Analyst Insight
Stockholders should review the proxy statement and vote their shares by returning the proxy card or participating in the virtual meeting.
Key Numbers
- 2024-04-24 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
- 09:00 — Annual Meeting Time (Time of the Annual Meeting of Stockholders)
Key Players & Entities
- ABEONA THERAPEUTICS INC. (company) — Registrant
- April 24, 2024 (date) — Annual Meeting date
- 9:00 a.m., Eastern Time (time) — Annual Meeting time
- www.virtualshareholdermeeting.com/ABEO2024 (url) — Webcast link for Annual Meeting
- Vishwas Seshadri (person) — President and Chief Executive Officer
FAQ
When did ABEONA THERAPEUTICS INC. file this DEF 14A?
ABEONA THERAPEUTICS INC. filed this Proxy Statement (DEF 14A) with the SEC on March 19, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ABEONA THERAPEUTICS INC. (ABEO).
Where can I read the original DEF 14A filing from ABEONA THERAPEUTICS INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ABEONA THERAPEUTICS INC..
What are the key takeaways from ABEONA THERAPEUTICS INC.'s DEF 14A?
ABEONA THERAPEUTICS INC. filed this DEF 14A on March 19, 2024. Key takeaways: The Annual Meeting of Stockholders for Abeona Therapeutics Inc. will be held virtually on April 24, 2024, at 9:00 a.m. Eastern Time.. Stockholders can attend, vote, and submit questions via a live webcast at www.virtualshareholdermeeting.com/ABEO2024.. The proxy statement provides details on the business to be considered at the meeting..
Is ABEONA THERAPEUTICS INC. a risky investment based on this filing?
Based on this DEF 14A, ABEONA THERAPEUTICS INC. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
What should investors do after reading ABEONA THERAPEUTICS INC.'s DEF 14A?
Stockholders should review the proxy statement and vote their shares by returning the proxy card or participating in the virtual meeting. The overall sentiment from this filing is neutral.
How does ABEONA THERAPEUTICS INC. compare to its industry peers?
Abeona Therapeutics Inc. is a biopharmaceutical company. This filing is a standard proxy statement for its annual shareholder meeting.
Are there regulatory concerns for ABEONA THERAPEUTICS INC.?
This filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, requiring public companies to provide shareholders with information before their annual meetings.
Industry Context
Abeona Therapeutics Inc. is a biopharmaceutical company. This filing is a standard proxy statement for its annual shareholder meeting.
Regulatory Implications
This filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, requiring public companies to provide shareholders with information before their annual meetings.
What Investors Should Do
- Review the proxy statement for details on proposals and voting matters.
- Vote your shares by returning the proxy card or participating in the virtual meeting.
- Ensure your proxy is submitted correctly and on time to be counted.
Key Dates
- 2024-04-24: Annual Meeting of Stockholders — Key date for shareholder voting and participation.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a proxy statement for the annual meeting. It does not contain comparative financial data from a previous filing.
Filing Stats: 4,499 words · 18 min read · ~15 pages · Grade level 12.8 · Accepted 2024-03-19 07:19:12
Key Financial Figures
- $0.01 — holders of its common stock, par value $0.01 per share (“Common Stock”),
Filing Documents
- formdef14a.htm (DEF 14A) — 749KB
- formdef14a_001.jpg (GRAPHIC) — 76KB
- formdef14a_002.jpg (GRAPHIC) — 88KB
- proxy_001.jpg (GRAPHIC) — 286KB
- proxy_002.jpg (GRAPHIC) — 392KB
- 0001493152-24-010421.txt ( ) — 1910KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management 11
Executive Compensation
Executive Compensation 13 Pay Versus Performance 16 Proposals to Be Voted Upon 19 Proposal 1 – Election of Directors 19 Proposal 2 – Approval of an Increase in the Number of Shares Reserved for Issuance Under the Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan 25 Proposal 3 – Advisory Vote on the Compensation of the Company’s Named Executive Officers 37 Proposal 4 – Ratification of Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm 38 Other Matters 3 9 Appendix A – Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan A-1 i PROXY This summary highlights information contained elsewhere in this proxy statement. This summary does not contain all information that you should consider, and you should review all of the information contained in the proxy statement before voting. Annual Meeting of Stockholders Date: April 24, 2024 Time: 9:00 a.m. Eastern Time Location: Online only at www.virtualshareholdermeeting.com/ABEO2024 . Stockholders will not be able to attend the Annual Meeting in person. Record Date: March 1, 2024 Voting: Stockholders as of the Record Date are entitled to vote. Each share of common stock is entitled to one vote. Proposals and Voting Recommendations Proposal No. Proposal Board Recommendation 1 To elect Vishwas Seshadri and Leila Alland as Class 2 Directors to hold office for a term of three years and until their successors are elected and qualified FOR EACH NOMINEE 2 To approve an increase in the number of shares reserved for issuance under the Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 1,700,000 to 3,200,000 shares FOR 3 To approve, on an advisory basis, the compensation of the Company’s named executive officers FOR 4 To ratify the appointment of Deloitte & Touche LLP as our independent registered
: Gender Identity
Part I: Gender Identity Directors 2 4 — 1
: Demographic Background
Part II: Demographic Background African American or Black — — — — Alaskan Native or Native American — — — — Asian — 1 — — Hispanic or Latinx — — — — Native Hawaiian or Pacific Islander — — — — White 2 3 — — Two or more Races or Ethnicities — — — — LGBTQ+ — 1 — — Did not disclose demographic background — — — 1 Board of Directors’ Role in Risk Oversight The Board is responsible for overseeing our management and operations, including overseeing our risk assessment and risk management functions. We believe that our directors provide effective oversight of risk management functions. We perform a risk review on a regular basis wherein the management team evaluates the risks we expect to face in the upcoming year and over a longer-term horizon. From this risk assessment, plans are developed to deal with the risks identified. The results of this risk assessment are provided to the Board for its consideration and review. In addition, members of our management periodically present to the Board the strategies, issues and plans for the areas of our business for which they are responsible. While the Board oversees risk management, our management is responsible for day-to-day risk management processes. Additionally, the Board requires that management raise exceptional issues to the Board. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that the Board leadership structure supports this approach. Code of Business Conduct and Ethics We have adopted a Code of Business Conduct and Ethics (the “Code”) that applies to all of our employees (including executive officers) and directors. The Code is available on our website at www.abeonatherapeutics.com under the he